|Lerisetron (Code C30143)|
|Terms & Properties|
Preferred Name: Lerisetron
Definition: The hydrochloride salt of a 2-piperazinylbenzimidazole-derivative serotonin type 3 (5-HT3) receptor antagonist with antiemetic activity. Lerisetron specifically binds to 5-HT3 receptors, located peripherally on vagus nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, which may result in suppression of chemotherapy-induced nausea and vomiting.
NCI-GLOSS Definition: A substance being studied in the treatment of nausea and vomiting caused by cancer treatment. Lerisetron is a type of serotonin receptor antagonist and a type of antiemetic.
NCI Metathesaurus Link: C0758799 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||143257-98-1 (see NLM ChemIDplus info)|
|FDA UNII Code||Q36R82SXRG|
|PDQ Closed Trial Search ID||37821|
|PDQ Open Trial Search ID||37821 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|